FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3142386369> ?p ?o ?g. }

• W3142386369 endingPage "1984" @default.
• W3142386369 startingPage "1970" @default.
• W3142386369 abstract "Physicochemical properties, in particular solubility and the associated bioavailability, are key factors in determining efficacy of poorly water-soluble drugs, which constitute 40% of new drugs in the market, and improving them is an important challenge for modern pharmacy. A recent strategy to achieve this goal is formation of stable co-amorphous solid dispersions with co-formers of low molecular weight. Here, the amorphization strategy was applied for low-soluble anti-hypertensive valsartan (VAL), an angiotensin II receptor blocker, and nicotinamide, which exhibits lung- and cardio-protective effects. Through interactions with the renin–angiotensin–aldosteron system, VAL may be used to treat both hypertension and the current pandemic coronavirus SARS-CoV-2 infection. Using mechanochemical and liquid- and solid-state approaches, solvated co-amorphous solid dispersions of VAL with nicotinamide were obtained. They were characterized by spectroscopic, thermal, and X-ray analyses. The density functional theory, quantum theory of atoms in molecules, and non-covalent interaction index calculations revealed the presence of two types of hydrogen bonds between VAL and NIC (i.e., N–H···O and O–H···O). One of them had a partially covalent character, which caused conformational changes in the flexible VAL molecule, restricting contribution of the tetrazolyl N–H donor and thus limiting the possibility of co-crystal formation. The recognized VAL/NIC1- and VAL/NIC2-type heterodimeric interactions were responsible for the excellent durability of the solid compositions and up to 24-fold better solubility than VAL alone. The synthesized dispersions constitute a new class of dually acting drugs, containing an active pharmaceutical ingredient (VAL) and supporting nutraceutical (nicotinamide)." @default.
• W3142386369 created "2021-04-13" @default.
• W3142386369 creator A5015280392 @default.
• W3142386369 creator A5064549072 @default.
• W3142386369 creator A5068370800 @default.
• W3142386369 creator A5083222849 @default.
• W3142386369 creator A5067026708 @default.
• W3142386369 date "2021-04-01" @default.
• W3142386369 modified "2023-10-18" @default.
• W3142386369 title "Role of Hydrogen Bonds in Formation of Co-amorphous Valsartan/Nicotinamide Compositions of High Solubility and Durability with Anti-hypertension and Anti-COVID-19 Potential" @default.
• W3142386369 cites W1498305210 @default.
• W3142386369 cites W1969169061 @default.
• W3142386369 cites W1978633893 @default.
• W3142386369 cites W1980614673 @default.
• W3142386369 cites W1981111904 @default.
• W3142386369 cites W1991418048 @default.
• W3142386369 cites W1993600548 @default.
• W3142386369 cites W1994893251 @default.
• W3142386369 cites W1999404597 @default.
• W3142386369 cites W2000811382 @default.
• W3142386369 cites W2004304738 @default.
• W3142386369 cites W2013065334 @default.
• W3142386369 cites W2017657147 @default.
• W3142386369 cites W2017689047 @default.
• W3142386369 cites W2023489366 @default.
• W3142386369 cites W2024328937 @default.
• W3142386369 cites W2029667189 @default.
• W3142386369 cites W2038083805 @default.
• W3142386369 cites W2039829919 @default.
• W3142386369 cites W2040432233 @default.
• W3142386369 cites W2040725117 @default.
• W3142386369 cites W2043203516 @default.
• W3142386369 cites W2048305487 @default.
• W3142386369 cites W2055663558 @default.
• W3142386369 cites W2058848030 @default.
• W3142386369 cites W2077541768 @default.
• W3142386369 cites W2089752619 @default.
• W3142386369 cites W2089962804 @default.
• W3142386369 cites W2095474273 @default.
• W3142386369 cites W2100462417 @default.
• W3142386369 cites W2111325726 @default.
• W3142386369 cites W2132525235 @default.
• W3142386369 cites W2134270369 @default.
• W3142386369 cites W2152247975 @default.
• W3142386369 cites W2169655552 @default.
• W3142386369 cites W2179159667 @default.
• W3142386369 cites W2214187833 @default.
• W3142386369 cites W2314228231 @default.
• W3142386369 cites W2314329582 @default.
• W3142386369 cites W2319914471 @default.
• W3142386369 cites W2322472795 @default.
• W3142386369 cites W2330409642 @default.
• W3142386369 cites W2333644404 @default.
• W3142386369 cites W2412361491 @default.
• W3142386369 cites W2427094903 @default.
• W3142386369 cites W2501241964 @default.
• W3142386369 cites W2522214061 @default.
• W3142386369 cites W2535027509 @default.
• W3142386369 cites W2538823927 @default.
• W3142386369 cites W2562746497 @default.
• W3142386369 cites W2601762250 @default.
• W3142386369 cites W2605822978 @default.
• W3142386369 cites W2780471111 @default.
• W3142386369 cites W2793361661 @default.
• W3142386369 cites W2794381070 @default.
• W3142386369 cites W288270944 @default.
• W3142386369 cites W2888095892 @default.
• W3142386369 cites W2903810116 @default.
• W3142386369 cites W2912004085 @default.
• W3142386369 cites W2969641100 @default.
• W3142386369 cites W2999932697 @default.
• W3142386369 cites W3006252254 @default.
• W3142386369 cites W3012974177 @default.
• W3142386369 cites W3013302817 @default.
• W3142386369 cites W3013564424 @default.
• W3142386369 cites W3016572296 @default.
• W3142386369 cites W3020511645 @default.
• W3142386369 cites W3023383663 @default.
• W3142386369 cites W3030177929 @default.
• W3142386369 cites W3046880631 @default.
• W3142386369 doi "https://doi.org/10.1021/acs.molpharmaceut.0c01096" @default.
• W3142386369 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8029446" @default.
• W3142386369 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33792313" @default.
• W3142386369 hasPublicationYear "2021" @default.
• W3142386369 type Work @default.
• W3142386369 sameAs 3142386369 @default.
• W3142386369 citedByCount "19" @default.
• W3142386369 countsByYear W31423863692021 @default.
• W3142386369 countsByYear W31423863692022 @default.
• W3142386369 countsByYear W31423863692023 @default.
• W3142386369 crossrefType "journal-article" @default.
• W3142386369 hasAuthorship W3142386369A5015280392 @default.
• W3142386369 hasAuthorship W3142386369A5064549072 @default.
• W3142386369 hasAuthorship W3142386369A5067026708 @default.
• W3142386369 hasAuthorship W3142386369A5068370800 @default.
• W3142386369 hasAuthorship W3142386369A5083222849 @default.
• W3142386369 hasBestOaLocation W31423863691 @default.
• W3142386369 hasConcept C112887158 @default.

• next